The month of October has had a number of trending news stories in refractive surgery. The most frequently viewed stories ranged from a distance learning course offered in Spain to a blog entry on the unavailability of toric multifocal IOLs in the U.S.
Dextenza has met the primary endpoint for treating ocular itching associated with allergic conjunctivitis in a phase 3 clinical trial, Ocular Therapeutix announced in a press release. For ocular itching, the Dextenza (sustained-release dexamethasone 0.4 mg) group showed a mean score of greater than 0.5 units at all time points and greater than 1 unit at a majority of the time points on day 7 after insertion compared with a placebo group (P
Contrast-balanced dichoptic movie viewing improves visual acuity in children with amblyopia, researchers report. Reuters Health Information
(MedPage Today) — CMS emphasizing pay-for-performance, Republicans seek premium support
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jg98wh/viral) has announced the addition of the “Viral Conjunctivitis – Pipeline Review, H2 2015” report to their offering. This report provides comprehensive inf…
Nicox reported €7 million in revenues in the first 9 months of this year compared with €3.2 million in the same period of 2014, according to a press release. “The first 9 months of 2015 were marked by the continuous growth of our European commercial operations, which increased by 119% over the same period of 2014, and as well as by the new drug application acceptance for filing of Vesneo, our leading nitric oxide-donating candidate partnered with Valeant in glaucoma,” Michele Garufi, CEO and chairman of Nicox, said in the release.